Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates

被引:45
|
作者
Hirt, Deborah [1 ,2 ]
Urien, Saik [1 ,2 ]
Rey, Elisabeth [3 ]
Arrive, Elise [4 ]
Ekouevi, Didier K. [5 ]
Coffie, Patrick [5 ]
Leang, Sim Kruy [6 ]
Lalsab, Sarita [7 ]
Avit, Divine [5 ]
Nerrienet, Eric [8 ]
McIntyre, James [7 ]
Blanche, Stephane [9 ]
Dabis, Francois [4 ]
Treluyer, Jean-Marc [1 ,2 ,3 ]
机构
[1] Univ Paris 05, EA3620, Paris, France
[2] Hop Tarnier, AP HP, Unite Rech Clin, F-75006 Paris, France
[3] Univ Paris 05, Hop Cochin St Vincent de Paul, AP HP, Serv Pharmacol Clin, Paris, France
[4] Univ Victor Segalen, INSERM, ISPED, U897, Bordeaux, France
[5] ANRS Abidjan, Programme PAC CI, Abidjan, Cote Ivoire
[6] Hop Calmette, Serv Gynecol Obstet, Phnom Penh, Cambodia
[7] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit PHRU, Johannesburg, South Africa
[8] Inst Pasteur Cambodge, Phnom Penh, Cambodia
[9] Univ Paris 05, Hop Necker Enfants Malad, Serv Immunol & Hematol Pediat, Paris, France
关键词
DISOPROXIL FUMARATE; RESISTANCE; NEVIRAPINE; TENOFOVIR; QUANTIFICATION; PHARMACOLOGY;
D O I
10.1128/AAC.00860-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters.h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg.liter(-1).h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg.liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.
引用
收藏
页码:1067 / 1073
页数:7
相关论文
共 50 条
  • [21] Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
    Karlsson, AC
    Gaines, H
    Sällberg, M
    Lindbäck, S
    Sönnerborg, A
    JOURNAL OF VIROLOGY, 1999, 73 (07) : 6191 - 6196
  • [22] Measles antibody in vaccinated human immunodeficiency virus type 1-infected children
    Arpadi, SM
    Markowitz, LE
    Baughman, AL
    Shah, K
    Adam, H
    Wiznia, A
    Lambert, G
    Dobroszycki, J
    Heath, JL
    Bellini, WJ
    PEDIATRICS, 1996, 97 (05) : 653 - 657
  • [23] Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: Vertical transmission and clades
    Palumbo, P
    Holland, B
    Dobbs, T
    Pau, CP
    Luo, CC
    Abrams, EJ
    Nesheim, S
    Vink, P
    Respess, R
    Bulterys, M
    JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (09): : 1120 - 1126
  • [24] Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania
    Chilongozi, Duvid
    Wang, Lei
    Brown, Lillian
    Taha, Taha
    Valentine, Melgan
    Emel, Lynda
    Sinkala, Moses
    Kafulafula, George
    Noor, Ramadhani A.
    Read, Jennifer S.
    Brown, Elizabeth R.
    Goldenberg, Robert L.
    Hoffman, Irving
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (09) : 808 - 814
  • [25] Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy
    Bellibas, SE
    Siddique, Z
    Dorr, A
    Bertasso, A
    Sista, P
    Kolis, SJ
    Cotler, S
    Delora, P
    Saroj, S
    Nubel, C
    Church, J
    Dunaway, T
    Cunningham, C
    Holz, W
    Emmanuel, P
    Russell, P
    Febo, I
    Davila, S
    Fisher, R
    Reininger, M
    Gay, H
    McNeeley, D
    Bhupali, C
    Secord, E
    Steinhilber, G
    Sleasman, J
    Delaney, C
    Spiegel, H
    Lee, M
    Wiznia, A
    Dorio, K
    Biernick, W
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (12) : 1137 - 1141
  • [26] Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women
    Schalkwijk, Stein
    Colbers, Angela
    Konopnicki, Deborah
    Gingelmaier, Andrea
    Lambert, John
    van der Ende, Marchina
    Molto, Jose
    Burger, David
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (08) : 1335 - 1341
  • [27] Hepatitis G virus infection in human immunodeficiency virus type 1-infected mothers and their children
    de Martino, M
    Azzari, C
    Resti, M
    Moriondo, M
    Rossi, ME
    Galli, L
    Vierucci, A
    JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (03): : 862 - 865
  • [28] Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India
    Mehendale, SM
    Bollinger, RC
    Kulkarni, SS
    Stallings, RY
    Brookmeyer, RS
    Kulkarni, SV
    Divekar, AD
    Gangakhedkar, RR
    Joshi, SN
    Risbud, AR
    Thakar, MA
    Mahajan, BA
    Kale, VA
    Ghate, MV
    Gadkari, DA
    Quinn, TC
    Paranjape, RS
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (16) : 1175 - 1179
  • [29] Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors
    Steiner, F
    Kind, C
    Aebi, LC
    Wyler-Lazarevitch, CA
    Cheseaux, JJ
    Rudin, C
    Molinari, L
    Nadal, D
    EUROPEAN JOURNAL OF PEDIATRICS, 2001, 160 (10) : 611 - 616
  • [30] Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children
    Schaaf, HS
    Geldenduys, A
    Gie, RP
    Cotton, MF
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (07) : 599 - 604